BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35348812)

  • 21. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
    Front Immunol; 2019; 10():1943. PubMed ID: 31475004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma.
    Nakashima M; Tanaka Y; Okamura H; Kato T; Imaizumi Y; Nagai K; Miyazaki Y; Murota H
    Cells; 2024 Jan; 13(2):. PubMed ID: 38247820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
    Duell J; Abrisqueta P; Andre M; Gaidano G; Gonzales-Barca E; Jurczak W; Kalakonda N; Liberati AM; Maddocks KJ; Menne T; Nagy Z; Tournilhac O; Kuffer C; Bakuli A; Amin A; Gurbanov K; Salles G
    Haematologica; 2024 Feb; 109(2):553-566. PubMed ID: 37646664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
    Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
    J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical study of CD19 detection methods post tafasitamab treatment.
    Ilieva K; Eberl M; Jaehrling J; Blair D; Patra-Kneuer M; Boxhammer R; Alvarez Arias D; Heitmüller C
    Front Immunol; 2023; 14():1274556. PubMed ID: 37928552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
    Awan FT; Lapalombella R; Trotta R; Butchar JP; Yu B; Benson DM; Roda JM; Cheney C; Mo X; Lehman A; Jones J; Flynn J; Jarjoura D; Desjarlais JR; Tridandapani S; Caligiuri MA; Muthusamy N; Byrd JC
    Blood; 2010 Feb; 115(6):1204-13. PubMed ID: 19965644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
    Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
    Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
    Klisovic RB; Leung WH; Brugger W; Dirnberger-Hertweck M; Winderlich M; Ambarkhane SV; Jabbour EJ
    Cancer; 2021 Nov; 127(22):4190-4197. PubMed ID: 34343354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    Davis JA; Shockley A; Glode AE
    J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
    [No Abstract]   [Full Text] [Related]  

  • 33. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
    Yang X; Min X; He W
    Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.
    Pievani A; Belussi C; Klein C; Rambaldi A; Golay J; Introna M
    Blood; 2011 Jan; 117(2):510-8. PubMed ID: 21048157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells.
    Wulf GG; Boehnke A; Chapuy B; Glass B; Hemmerlein B; Schroers R; Brenner MK; Truemper L
    Haematologica; 2006 Jul; 91(7):886-94. PubMed ID: 16818275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.